Related Experiment Videos

Structure of human methionine aminopeptidase-2 complexed with fumagillin

S Liu1, J Widom, C W Kemp

  • 1J. Clardy, Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, NY 14853-1301, USA.

Science (New York, N.Y.)
|November 13, 1998
PubMed

Insights

Fumagillin, an anticancer drug candidate, targets methionine aminopeptidase-2 (MetAP-2) by forming a covalent bond. Structural analysis reveals key interactions for drug design and specificity against MetAP-2.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Pharmacology

Background:

  • Fumagillin, a fungal metabolite, inhibits angiogenesis and is a potential anticancer agent.
  • Its molecular target is methionine aminopeptidase-2 (MetAP-2).

Purpose of the Study:

  • To elucidate the structural basis of fumagillin's inhibition of MetAP-2.
  • To understand the specificity of fumagillin for MetAP-2 over MetAP-1.

Main Methods:

  • X-ray crystallography at 1.8 A resolution.
  • Analysis of free and inhibited human MetAP-2 structures.

Main Results:

  • A covalent bond is formed between fumagillin's epoxide and histidine-231 in MetAP-2's active site.
  • Hydrophobic and water-mediated interactions contribute to binding affinity.
  • Structural determinants for MetAP-2 specificity over MetAP-1 were identified.

Conclusions:

  • The crystal structure provides a detailed understanding of fumagillin-MetAP-2 interactions.
  • This structural information is crucial for structure-based design of novel fumagillin analogs.

Related Concept Videos